Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. filed Amendment No. 1 to its registration statement on Form S-1 as an exhibits-only update. The amendment leaves the main prospectus unchanged and adds the facing page, an explanatory note, Part II information, signatures, and a detailed exhibit index.
The filing estimates issuance and distribution costs for the common stock being registered at about $115,000, including a $3,477.32 SEC registration fee, $20,500 in accounting fees, $85,000 in legal fees, and other miscellaneous expenses. It also describes indemnification provisions for directors and officers under Delaware law and restates standard Securities Act undertakings related to post-effective amendments and liability.
Vaxart, Inc. is registering up to 32,914,599 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a $25 million committed equity purchase agreement. The total includes up to 32,467,532 Purchase Shares that Vaxart may sell to Lincoln Park and 447,067 Commitment Shares already issued as consideration.
Vaxart will not receive proceeds from Lincoln Park’s resale of these shares but may raise up to $25 million when it sells Purchase Shares under the agreement. Shares outstanding were 241,973,011 before the offering and would rise to 274,440,543 if all Purchase Shares are issued, meaning substantial potential dilution.
The company trades on the OTCQX under “VXRT” after a Nasdaq delisting and highlights risks from stock price volatility, reliance on BARDA funding for its COVID-19 program, ongoing losses, and the need for additional capital despite $61.0 million in cash, cash equivalents and investments as of March 31, 2026.
Vaxart, Inc. reported a profitable quarter for the three months ended March 31, 2026, driven mainly by U.S. government funding and a new collaboration. Total revenue rose to $39.2 million from $20.9 million, powered by $36.4 million from BARDA government contracts and $2.8 million of collaboration revenue from its Dynavax (now Sanofi) license deal.
Operating expenses were $34.1 million, slightly below the prior year, leading to operating income of $5.2 million versus a loss of $14.9 million a year earlier. Net income reached $5.2 million, or $0.02 per diluted share, compared with a net loss of $15.6 million, or $(0.07) per share.
Vaxart ended the quarter with $61.0 million in cash, cash equivalents and short-term investments and expects this to fund planned operations for at least 12 months, with cash runway projected into the second quarter of 2027. The company also put in place a $25.0 million equity line of credit and has an at-the-market program available under a new 2026 shelf registration to support future capital needs.
Vaxart, Inc. reported a strong turnaround for the first quarter of 2026, with revenue of $39.2 million and net income of $5.2 million, compared with a net loss a year earlier. The improvement reflects higher revenue while keeping operating expenses roughly flat.
The company ended March 31, 2026 with $61.0 million in cash, cash equivalents, and investments, which it expects to fund operations into the second quarter of 2027. Vaxart is running a BARDA‑supported Phase 2b COVID‑19 oral pill vaccine trial, with topline 12‑month safety and efficacy data from a 400‑person sentinel cohort anticipated in the second quarter of 2026 and primary data from a 5,000‑participant main cohort expected in early 2027.
Vaxart also scheduled a live stockholder fireside chat for May 8, 2026 to discuss these updates and answer investor questions.
Vaxart, Inc. has filed a prospectus supplement to sell up to $49,772,479 of common stock through an at‑the‑market (ATM) offering under a Sales Agreement with Citizens JMP Securities, LLC and B. Riley Securities, Inc. The Sales Agents may sell shares from time to time on Nasdaq, other trading venues, or in privately negotiated transactions, and are entitled to commissions up to 3% of gross sales.
The prospectus supplement bases the offering on 241,414,053 shares outstanding as of April 10, 2026 and illustrates a pro forma share count of up to 320,417,987 shares assuming sales at $0.63 per share. Net proceeds will equal gross proceeds less commissions and offering expenses; proceeds are intended for general corporate purposes including working capital, operating expenses and capital expenditures. The filing discloses a going‑concern funding need and states cash, cash equivalents and investments of $63.8 million as of December 31, 2025.
Vaxart, Inc. director James B. Breitmeyer reported receiving equity compensation in the form of common shares and stock options. He was granted 78,800 shares of Common Stock upon vesting of restricted stock units, with the underlying award vesting in three equal annual installments starting from the grant date, subject to his continued service on the Board of Directors.
He was also granted a stock option for 157,400 shares of Common Stock at an exercise price of $0.7399 per share, expiring on April 23, 2036. The option vests in three equal annual installments from the grant date, also conditioned on continued Board service. These are compensation-related awards rather than open‑market purchases or sales.
Vaxart, Inc. director James B. Breitmeyer filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing lists him as a director of Vaxart but does not report any share purchases, sales, or other transactions in the company’s securities.
Vaxart, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to provide updated Part III information on directors, executive officers, corporate governance, executive and director compensation, security ownership, related‑party transactions, and auditor fees.
The filing shows a predominantly independent board, active audit, compensation, and nominating committees, and detailed pay and equity awards for senior management and non‑employee directors. It also describes clawback, insider trading, anti‑hedging, and governance policies, plus 2025 cash and stock retainers for directors.
Vaxart, Inc. appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately, following a recommendation from the Nominating and Governance Committee. The Board determined that he meets its independence standards.
Dr. Breitmeyer brings over 35 years of biopharmaceutical experience, including leadership roles at Altay Therapeutics, Oncternal Therapeutics, Bavarian Nordic, Eli Lilly, Cadence Pharmaceuticals and others. He has led clinical programs resulting in eight FDA product approvals and multiple regulatory successes in the U.S., Europe and Japan, including vaccine-related work at Bavarian Nordic.
He will receive cash and equity compensation under Vaxart’s standard Non-Employee Director Compensation Program and has entered into the company’s standard indemnification agreement. A press release announcing his appointment was furnished as an exhibit and is not deemed filed for Exchange Act liability purposes.